Linatra (Linagliptin)

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus.

• Type 2 diabetes mellitus: improves glycaemic control as part of diet and exercise therapy.
• Monotherapy: lowers HbA1c when used alone in patients inadequately controlled by lifestyle alone.
• Combination therapy: enhances glucose control when added to metformin, sulfonylureas, or insulin.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which degrades the incretin hormones GLP-1 and GIP. By blocking DPP-4, linagliptin increases endogenous GLP-1 and GIP levels, enhancing glucose-dependent insulin secretion and suppressing glucagon release after meals, thereby reducing post-prandial and overall blood glucose concentrations without causing hypoglycaemia in the absence of other agents.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild gastrointestinal discomfort reported in some patients.
• Headache: transient headache occurring early in therapy.
• Nasopharyngitis: upper respiratory tract infection symptoms.
• Diarrhoea: loose stools, usually self-limiting.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with elevated enzymes, requiring immediate medical attention.
• Severe hypersensitivity: rash, angioedema, or anaphylactic reactions.
• Hepatic injury: marked elevation of liver enzymes or jaundice.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: no dose adjustment required, but monitor renal function periodically.
• Hepatic impairment: use with caution in patients with moderate liver disease; assess liver enzymes.
• Cardiovascular risk: evaluate for heart failure symptoms, although no direct contraindication.
• Pregnancy and lactation: avoid use unless potential benefit outweighs risk, as safety data are limited.
• Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Linagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin exposure.
• Combination with insulin secretagogues (e.g., sulfonylureas) without dose adjustment: increased risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

• Diuretics (e.g., thiazides): may enhance hypoglycaemic effect.
• ACE inhibitors or ARBs: monitor blood pressure and renal function.
• Anticoagulants (e.g., warfarin): observe INR as linagliptin may affect metabolism.